Under 10% of patients that would benefit from GLP-1 drugs like Wegovy can access them, states the World Health Organization as it releases its initial recommendations on the medications.
With more than one billion individuals worldwide now classified as obese, it is urging increased and just availability to this class of drugs.
According to estimates, more than two billion are projected to be obese by 2030 without intervention.
"The new guidance recognises that excess weight is a long-term condition that can be addressed with comprehensive and ongoing treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major hurdles to widespread availability to the treatments that can aid individuals in losing significant weight, notes the agency.
Skinny Jab Scarcity
Even in the present most favorable scenario, the production of these medications might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the health organization.
The recommendation encourages nations and manufacturers to widen access, via strategies like patent sharing.
The intellectual property rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026.
The Way Obesity Jabs Function
GLP-1 drugs imitate a biological compound to reduce digestion speed, suppress the appetite and enhance the sense of being full so users eat less.
People usually begin shedding pounds after several weeks of beginning the once-weekly jabs.
Studies suggests people may see weight return a year later of stopping the treatment, because their usual food cravings return.
To be above a healthy weight raises your likelihood for developing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight concerns individuals in every country and was responsible for millions of deaths worldwide in 2024, as per the WHO.
